Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma

Key Points

• Improved outcomes were associated with the use of ezabenlimab in stage 3 squamous cell carcinoma, indicating efficacy.
• The treatment protocol included induction chemotherapy followed by adaptive chemoradiotherapy to maximize effects.
• This approach combines targeted therapy with traditional methods, aiming to enhance overall treatment response.
• These findings support further exploration of ezabenlimab as a potential standard in treatment for anal carcinoma.